Bausch+Lomb IPO Presentation Deck

Broad portfolio in large Ophthalmic Pharmaceuticals market Ophthalmic Pharmaceuticals is a large market, supported by strong mega trends... Addressable indications S Age-related macular degeneration² Glaucoma Dry eye Conjunctivitis Ocular pain & inflammation³ Other4 BAUSCH+ LOMB Global revenue, $B¹ 2 -2 -2 -2 5 12 -$26B¹ Mega Trends Aging population driving greater eye needs • Increasing myopia prevalence due to screen time Rising diabetes prevalence • Growing access to eye care and insurance 1. As of 2019. Source: OPHTHALMOLOGY COMPANY & DRUG INSIGHTS Clarivate publication May 2021; management estimates 2. Includes wet and dry AMD 3. Includes uveitis, in addition to ocular pain and Inflammation Largest portfolio of ~100 products5 drives diversity of revenue across indications (No product >15% of revenue) B+L Products CUTED 4. Includes other corneal and external eye disorders, myopia, other retinal disorders, inherited retinal diseases, and other ophthalmology treatments 5. Source: Evaluate Pharma Visudyne® VyzultaⓇ LacrisertⓇ Zylet® ProlensaⓇ In-market Istatol® Minims® Floxal® LotemaxⓇ Timoptic® BesivanceⓇ OPHTHALMIC PHARMACEUTICALS Yellox® Pipeline Ranibizumab Biosimilar Nov03 XIPERE Xipere ™ Launching Now Low dose atropine spray 30

View entire presentation